Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	10^th February 2023

2. INTERESTS AND SHORT POSITIONS

a. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	5,136,713 (2.245%)		24,412 (0.011%)
(2) Derivatives (other than options)			621 (0.000%)
(3) Options and agreements to purchase/sell	76,200 (0.033%)		479,200 (0.209%)
Total	5,212,913 (2.279%)		504,233 (0.220%)

b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

1. DEALINGS (Note 4)

a. Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Purchase	100	109.30
Purchase	1,153	109.32
Purchase	300	109.35
Purchase	3,290	109.39
Purchase	418	109.40
Purchase	1	109.37
Purchase	1,400	109.77
Purchase	1,101	109.33
Purchase	837	109.57
Purchase	200	109.34
Purchase	1,200	109.38
Purchase	2	109.48
Purchase	49	109.47
Purchase	51	109.55
Purchase	39	109.61
Purchase	2	109.41
Sale	9	109.48
Sale	45	109.47
Sale	196	109.50
Sale	102	109.51
Sale	1	109.49
Sale	92	109.55
Sale	22	109.52
Sale	1	109.45
Purchase	1,167	109.42
Sale	74	109.46
Sale	193	109.40
Sale	105	109.28
Sale	39	109.61
Sale	382	109.57
Sale	982	109.54
Sale	99	109.58
Sale	2	109.41
Sale	65	109.64
Sale	47	109.81
Sale	141	109.55
Purchase	45	109.42
Sale	49	109.42
Purchase	201	109.53
Purchase	3,918	109.48
Purchase	864	109.47
Purchase	4,934	109.50
Purchase	37,380	109.51
Purchase	7,711	109.49
Purchase	1,649	109.55
Purchase	1,966	109.52
Purchase	9,300	109.45
Purchase	441	109.42
Purchase	1,579	109.46
Sale	1	109.46
Sale	2	109.40
Purchase	1,003	109.56
Purchase	565	109.44
Purchase	100	109.76
Purchase	3,263	109.61
Purchase	439	109.57
Purchase	4,165	109.62
Purchase	1,268	109.70
Purchase	31	109.78
Purchase	92	109.43
Purchase	391	109.74
Purchase	1,077	109.54
Purchase	300	109.58
Purchase	88	109.48
Purchase	30	109.47
Purchase	5	109.50
Purchase	19	109.51
Purchase	38	109.49
Purchase	14	109.55
Purchase	20	109.52
Purchase	62	109.45
Purchase	34	109.46
Purchase	3	109.75
Purchase	30	109.56
Purchase	2	109.44
Purchase	16	109.80
Purchase	6	109.59
Purchase	1	109.69
Purchase	1	109.54
Purchase	43	109.71
Purchase	1,813	109.53
Sale	94	109.47
Sale	1,670	109.50
Sale	212	109.49
Purchase	25	109.52

b. Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

c. Options transactions in respect of existing relevant securities

i. Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price (USD)	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
Put Option	Purchased	200	105.00	American	2/17/2023
Put Option	Purchased	319,800	100.00	American	3/17/2023

ii. Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

d. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	13^th February 2023
Contact name	Roisin Nagle
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Call Option	Written	29,000	110.00	American	2/17/2023
IE00BQPVQZ61	Call Option	Purchased	29,100	100.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	1,500	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	3,000	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	3,000	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	400	115.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	400	115.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	3,500	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	62,400	110.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	4,100	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	3,500	110.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	3,100	85.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	2,500	90.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	100	95.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	23,800	100.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	20,500	105.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	400	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	400	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	1,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put option	Purchased	319,800	100.00	American	3/17/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1062712

Time of Receipt (offset from UTC): 20230213T135716+0000